#safety - Techseriesinsight

May 30, 2025
PRNewswire
Healthcare

Michelle Monaghan Champions Skin Health in New Awareness Campaign

Healthy skin is more than surface-level, it’s a key part of our overall well-being. That’s why Mediaplanet is proud to launch its “Skin Health” campaign, aimed at empowering individuals...

May 26, 2025
PRNewswire
Artificial Intelligence

VUNO Showcases DeepCARS® at AACN NTI 2025, Highlighting AI-Driven Cardiac Arrest Risk Prediction

VUNO, a global medical AI company, presented its flagship solution VUNO Med®–DeepCARS® at the 2025 National Teaching Institute & Critical Care Exposition (NTI), hosted by the American Association of Critical-Care...

April 29, 2025
PRNewswire
Biotechnology

Announcing Veeva AI

Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve...

April 17, 2025
PRNewswire
Cloud

Huawei Launches Five Aviation Solutions to Accelerate Intelligence USA – English

During the Passenger Terminal Expo 2025, Huawei launched five aviation solutions including the Smart Airport Intelligent Operation Center (IOC) to advance intelligent industry upgrades. Huawei deeply integrates novel technologies...

April 15, 2025
PRNewswire
Biotechnology

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial...

April 8, 2025
PRNewswire
Healthcare

Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis

Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the first patient has been dosed in its CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in Australia. The trial will evaluate...

March 26, 2025
PRNewswire
Biotechnology

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a...